RedHill Biopharma (RDHL) Equity Ratio (2012 - 2025)

RedHill Biopharma (RDHL) has 14 years of Equity Ratio data on file, last reported at 0.17 in Q4 2025.

• Equity Ratio for Q4 2025 came in at 0.17, up 164.88% year-over-year; the trailing twelve-month figure through Dec 2025 was 0.17 (up 164.88% YoY), and the FY2025 annual result was 0.17, up 164.88% from the prior year.
• Equity Ratio advanced to 0.17 in Q4 2025 per RDHL's latest filing, from 0.24 in the prior quarter.
• Over five years, Equity Ratio peaked at 0.17 in Q4 2025 and troughed at 0.3 in Q4 2022.
• A 5-year average of 0.08 and a median of 0.1 in 2021 frame the typical range for Equity Ratio.
• The sharpest annual moves came in 2022 and 2025: Equity Ratio slumped 721.96% in 2022, then surged 164.88% in 2025.
• A 5-year view of Equity Ratio shows it stood at 0.05 in 2021, then plunged by 721.96% to 0.3 in 2022, then soared by 129.47% to 0.09 in 2023, then slumped by 389.11% to 0.26 in 2024, then surged by 164.88% to 0.17 in 2025.
• Business Quant data shows RDHL's Equity Ratio at 0.17 in Q4 2025, 0.24 in Q2 2025, and 0.26 in Q4 2024.